Status:
COMPLETED
Study Evaluating LXR-623 in Healthy Subjects
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Healthy
Eligibility:
All Genders
19-50 years
Phase:
PHASE1
Brief Summary
To evaluate the safety and tolerability of a single dose of LXR-623 in healthy subjects.
Eligibility Criteria
Inclusion
- Inclusion:
- Healthy, men or women, aged 19-50 years
- Exlcusion:
- Use of any investigational or prescription drug within 30 days before study start
- Any clinically imprtant medical disease or abnormal laboratory test results
Exclusion
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00366522
Start Date
August 1 2006
End Date
September 1 2006
Last Update
August 7 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lincoln, Nebraska, United States, 68502